Equities analysts expect Danaher Co. (NYSE:DHR) to report earnings of $1.15 per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Danaher’s earnings. The highest EPS estimate is $1.18 and the lowest is $1.14. Danaher reported earnings of $1.05 per share during the same quarter last year, which indicates a positive year over year growth rate of 9.5%. The firm is scheduled to report its next quarterly earnings results before the market opens on Tuesday, January 30th.
According to Zacks, analysts expect that Danaher will report full-year earnings of $3.99 per share for the current fiscal year, with EPS estimates ranging from $3.97 to $4.02. For the next year, analysts expect that the firm will post earnings of $4.32 per share, with EPS estimates ranging from $4.30 to $4.36. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Danaher.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The company had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. During the same period in the previous year, the firm earned $0.87 EPS. The firm’s revenue was up 9.6% compared to the same quarter last year.
A number of research analysts recently commented on the company. Stifel Nicolaus reissued a “buy” rating and issued a $110.00 price target on shares of Danaher in a report on Friday. Robert W. Baird reissued a “buy” rating on shares of Danaher in a report on Friday, January 12th. Royal Bank of Canada reissued a “hold” rating and issued a $96.00 price target on shares of Danaher in a report on Thursday, January 4th. Evercore ISI assumed coverage on Danaher in a report on Wednesday, January 3rd. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $95.86.
Danaher (DHR) traded up $0.82 during midday trading on Thursday, reaching $100.56. The company had a trading volume of 2,120,486 shares, compared to its average volume of 1,779,936. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher has a one year low of $78.97 and a one year high of $100.88. The stock has a market cap of $69,950.03, a PE ratio of 29.66, a PEG ratio of 2.18 and a beta of 1.02.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be issued a dividend of $0.14 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.56%. Danaher’s dividend payout ratio (DPR) is 16.52%.
In other news, CFO Daniel L. Comas sold 88,184 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the sale, the chief financial officer now directly owns 227,816 shares of the company’s stock, valued at approximately $20,735,812.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald J. Ehrlich sold 10,578 shares of the company’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the sale, the director now directly owns 104,621 shares in the company, valued at $9,501,679.22. The disclosure for this sale can be found here. Insiders have sold a total of 273,810 shares of company stock worth $25,218,813 over the last ninety days. Insiders own 12.20% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Danaher by 30.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 39,685 shares of the conglomerate’s stock worth $3,944,000 after acquiring an additional 9,268 shares in the last quarter. Intermede Investment Partners Ltd increased its position in shares of Danaher by 4.9% during the 4th quarter. Intermede Investment Partners Ltd now owns 465,665 shares of the conglomerate’s stock valued at $43,223,000 after purchasing an additional 21,809 shares during the last quarter. TRUE Private Wealth Advisors bought a new position in shares of Danaher during the 4th quarter valued at approximately $484,000. Catawba Capital Management VA increased its position in shares of Danaher by 8.0% during the 4th quarter. Catawba Capital Management VA now owns 11,096 shares of the conglomerate’s stock valued at $1,030,000 after purchasing an additional 823 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Danaher by 289.6% during the 4th quarter. State of Alaska Department of Revenue now owns 66,724 shares of the conglomerate’s stock valued at $6,192,000 after purchasing an additional 49,596 shares during the last quarter. 76.11% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/danaher-co-dhr-expected-to-announce-earnings-of-1-15-per-share.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Get a free copy of the Zacks research report on Danaher (DHR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.